原薬中間体の世界市場レポート 2025年

原薬中間体市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）7.5％で2,057億7,000万米ドルに成長します。この予測期間における成長の背景には、個別化医療に対する需要の高まり、新興市場からの医薬品輸出の増加、生活習慣病の流行、新規ドラッグデリバリーシステムに対する需要の高まり、生物製剤やバイオシミラーの採用拡大などがあります。この期間に予想される主要動向には、上流プロセスと下流プロセスの統合、パイロットテストへのデジタルツインの利用、中間体合成のための生体触媒の進歩、スケールアッププロセスへの自動化の導入、廃棄物削減技術の革新などがあります。

医薬品に対する需要の高まりが、今後数年間の原薬中間体市場の成長を牽引すると予想されます。医薬品は、人間や動物の病気や病状を診断、治療、予防、治癒するために使用される物質や化合物です。このような需要の増加は、主に長期的な治療と一貫したヘルスケア管理を必要とする慢性疾患の有病率の増加によって促進されています。原薬中間体は、医薬品有効成分の効率的な合成と品質保証を可能にすることで、医薬品製造において重要な役割を果たしています。例えば2023年4月、米国を拠点とするシンクタンク、米国大西洋評議会は、米国が2022年に中国から輸入する原薬は14億8,449万米ドル相当で、2021年の14億3,708万米ドルから増加していると報告しました。このように、医薬品需要の高まりが原薬中間体市場の拡大に大きく寄与しています。

原薬中間体市場の主要企業は、治療成績の向上と治療の多様化のために、消化管API中間体のような革新的な治療法の開発を優先しています。消化器原薬中間体は、消化器系の疾患を治療するための原薬の製造に使用される必須化合物です。例えば、2023年10月、中国の製薬会社である湖南華騰製薬は、製薬産業の高まるニーズに対応するため、フェクスプラザンとボノプラザンの中間体を発表しました。これらの中間体は適正製造基準（GMP）グレードと非GMPグレードの両方があり、産業のベンチマークを上回る高純度レベルを保証しています。研究開発と商業規模の生産の両方に柔軟な選択肢を提供できるように設計されたこの新発売は、医薬品開発に高品質で信頼性の高い成分を提供することにより、革新的な消化管治療に対する需要の増加をサポートします。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、コロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の原薬中間体：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の原薬中間体市場：成長率分析
• 世界の原薬中間体市場の実績：規模と成長、2019～2024年
• 世界の原薬中間体市場の予測：規模と成長、2024～2029年、2034年
• 世界の原薬中間体：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の原薬中間体市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• バルク医薬品中間体
• 化学中間体
• 世界の原薬中間体市場：性質別、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 植物由来中間体
• 動物由来中間体
• 微生物中間体
• 合成天然物
• 生体変換中間体
• 世界の原薬中間体市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 鎮痛剤
• 抗糖尿病薬
• 抗感染症薬
• 心血管薬
• 抗がん剤
• その他
• 世界の原薬中間体市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 製薬会社
• 研究機関
• 契約製造組織
• その他
• 世界の原薬中間体市場、バルク医薬品中間体のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 合成中間体
• バイオテクノロジー中間体
• ペプチド中間体
• ステロイド中間体
• アミノ酸中間体
• 世界の原薬中間体市場、化学中間体のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• キラル中間体
• 複素環中間体
• 有機金属中間体
• 芳香族中間体
• 脂肪族中間体

第7章 地域別・国別分析

• 世界の原薬中間体市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の原薬中間体市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 原薬中間体市場：競合情勢
• 原薬中間体市場：企業プロファイル
  • Hetero Labs Ltd.
  • Aurobindo Pharma Ltd.
  • Ipca Laboratories Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Ltd.

第31章 その他の大手企業と革新的企業

• Cadila Pharmaceuticals Ltd.
• Lupin Ltd.
• Torrent Pharmaceuticals Ltd.
• Mankind Pharma Ltd.
• Divis Laboratories Ltd.
• Laurus Labs Ltd.
• Jubilant Pharmova Ltd.
• Piramal Pharma Ltd.
• Cambrex Corporation
• Alembic Pharmaceuticals Ltd.
• Granules India Ltd.
• JB Chemicals and Pharmaceuticals Ltd.
• Hovione Holdings S.A.
• Vasudha Pharma Chem Ltd.
• Concord BIoTech Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 原薬中間体市場、2029年：新たな機会を提供する国
• 原薬中間体市場、2029年：新たな機会を提供するセグメント
• 原薬中間体市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

An active pharmaceutical ingredient (API) intermediate is a compound generated during the synthesis of an API, acting as a vital precursor or building block before the final active pharmaceutical ingredient is obtained. It undergoes additional chemical reactions or purification processes to become the finished pharmaceutical product.

API intermediates are primarily categorized into bulk drug intermediates and chemical intermediates. Bulk drug intermediates are chemical substances used as raw materials in the synthesis of APIs. These intermediates can be derived from natural sources-such as plants, animals, or microbes-or classified under synthetic natural products and biotransformed intermediates. They are extensively utilized in the manufacturing of various drugs, including analgesics, antidiabetic agents, anti-infectives, cardiovascular medications, anticancer treatments, and more. The end users of these intermediates include pharmaceutical companies, research institutions, contract manufacturing organizations (CMOs), and other related entities.

The API intermediate market research report is one of a series of new reports from The Business Research Company that cover API intermediate market statistics, including the API intermediate industry's global market size, regional shares, competitors with the API intermediate market share, detailed API intermediate market segments, market trends and opportunities, and any further data you may need to thrive in the API intermediate market. This API intermediate market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The active pharmaceutical ingredient (API) intermediate market size has grown strongly in recent years. It will grow from $142.83 billion in 2024 to $153.97 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth during the historic period can be attributed to the rising demand for pharmaceutical products, increased adoption of synthetic and biopharmaceutical drugs, growing production of generic medications, enhanced regulatory support and approvals, and heightened investment in pharmaceutical research and development.

The active pharmaceutical ingredient (API) intermediate market size is expected to see strong growth in the next few years. It will grow to $205.77 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The projected growth in the forecast period can be attributed to the rising demand for personalized medicine, increasing pharmaceutical exports from emerging markets, growing prevalence of lifestyle-related diseases, heightened demand for novel drug delivery systems, and greater adoption of biologics and biosimilars. Key trends expected during this period include the integration of upstream and downstream processes, use of digital twins for pilot testing, advancements in biocatalysis for intermediate synthesis, incorporation of automation in scale-up processes, and innovations in waste reduction technologies.

The rising demand for pharmaceutical products is expected to drive the growth of the active pharmaceutical ingredient (API) intermediate market in the coming years. Pharmaceutical products are substances or compounds used to diagnose, treat, prevent, or cure diseases and medical conditions in humans or animals. This growing demand is primarily fueled by the increasing prevalence of chronic diseases that require long-term treatment and consistent healthcare management. API intermediates play a crucial role in pharmaceutical manufacturing by enabling the efficient synthesis and quality assurance of active pharmaceutical ingredients. For example, in April 2023, the Atlantic Council of the United States, a U.S.-based think tank, reported that the United States imported $1,484.49 million worth of APIs from China in 2022, up from $1,437.08 million in 2021. Thus, the rising demand for pharmaceutical products is contributing significantly to the expansion of the API intermediate market.

Leading companies in the active pharmaceutical ingredient (API) intermediate market are prioritizing the development of innovative therapies, such as gastrointestinal API intermediates, to improve treatment outcomes and diversify their therapeutic offerings. Gastrointestinal API intermediates are essential chemical compounds used in the production of APIs for treating disorders of the digestive system. For example, in October 2023, Hunan Huateng Pharmaceutical, a China-based pharmaceutical company, introduced Fexuprazan and Vonoprazan intermediates to address the growing needs of the pharmaceutical industry. These intermediates are available in both Good Manufacturing Practice (GMP) and non-GMP grades, ensuring high purity levels that exceed industry benchmarks. Designed to offer flexible options for both research and commercial-scale production, this launch supports the increasing demand for innovative gastrointestinal treatments by providing high-quality, reliable components for drug development.

In March 2024, International Chemical Investors Group (ICIG), a Luxembourg-based chemicals company, acquired Vasant Chemicals Pvt. Ltd. for an undisclosed amount. This acquisition is intended to enhance ICIG's position in the specialty chemicals market by expanding its manufacturing and distribution capabilities, particularly in India and across Asia. Vasant Chemicals Pvt. Ltd., based in India, specializes in the production of active pharmaceutical ingredient (API) intermediates.

Major players in the active pharmaceutical ingredient (api) intermediate market are Hetero Labs Ltd., Aurobindo Pharma Ltd., Ipca Laboratories Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Cadila Pharmaceuticals Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd., Mankind Pharma Ltd., Divis Laboratories Ltd., Laurus Labs Ltd., Jubilant Pharmova Ltd., Piramal Pharma Ltd., Cambrex Corporation, Alembic Pharmaceuticals Ltd., Granules India Ltd., JB Chemicals and Pharmaceuticals Ltd., Hovione Holdings S.A., Vasudha Pharma Chem Ltd., Concord Biotech Ltd., ABA Chemicals Private Limited, Clare Laboratories Pvt Ltd., Ind-Swift Laboratories Ltd., Panacea Biotec Ltd., RPG Life Sciences Ltd., Jay Finechem Industries Ltd., Glenmark Life Sciences Ltd., Suven Pharmaceuticals Ltd., IOL Chemicals and Pharmaceuticals Ltd.

North America was the largest region in the active pharmaceutical ingredient (API) intermediate market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in active pharmaceutical ingredient (API) intermediate report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the active pharmaceutical ingredient (API) intermediate market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The active pharmaceutical ingredient (API) intermediate market consists of sales of chiral intermediates, custom intermediates, heterocyclic intermediates, peptide intermediates, and polymer intermediates. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Active Pharmaceutical Ingredient (API) Intermediate Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on active pharmaceutical ingredient (api) intermediate market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for active pharmaceutical ingredient (api) intermediate ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The active pharmaceutical ingredient (api) intermediate market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Bulk Drug Intermediates; Chemical Intermediates
• 2) By Natural: Plant-Derived Intermediates; Animal-Derived Intermediates; Microbial Intermediates; Synthetic Natural Products; Biotransformed Intermediates
• 3) By Application: Analgesics; Antidiabetic Drugs; Anti-Infective Drugs; Cardiovascular Drugs; Anticancer Drugs; Other Applications
• 4) By End-User: Pharmaceutical Companies; Research Institutes; Contract Manufacturing Organizations; Other End-Users

Subsegments

• 1) By Bulk Drug Intermediates: Synthetic Intermediates; Biotech Intermediates; Peptide Intermediates; Steroidal Intermediates; Amino Acid Intermediates
• 2) By Chemical Intermediates: Chiral Intermediates; Heterocyclic Intermediates; Organometallic Intermediates; Aromatic Intermediates; Aliphatic Intermediates
• Companies Mentioned: Hetero Labs Ltd.; Aurobindo Pharma Ltd.; Ipca Laboratories Ltd.; Dr. Reddy's Laboratories Ltd.; Cipla Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Active Pharmaceutical Ingredient (API) Intermediate Market Characteristics

3. Active Pharmaceutical Ingredient (API) Intermediate Market Trends And Strategies

4. Active Pharmaceutical Ingredient (API) Intermediate Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Active Pharmaceutical Ingredient (API) Intermediate Growth Analysis And Strategic Analysis Framework

• 5.1. Global Active Pharmaceutical Ingredient (API) Intermediate PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Active Pharmaceutical Ingredient (API) Intermediate Market Growth Rate Analysis
• 5.4. Global Active Pharmaceutical Ingredient (API) Intermediate Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Active Pharmaceutical Ingredient (API) Intermediate Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Active Pharmaceutical Ingredient (API) Intermediate Total Addressable Market (TAM)

6. Active Pharmaceutical Ingredient (API) Intermediate Market Segmentation

• 6.1. Global Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bulk Drug Intermediates
• Chemical Intermediates
• 6.2. Global Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Plant-Derived Intermediates
• Animal-Derived Intermediates
• Microbial Intermediates
• Synthetic Natural Products
• Biotransformed Intermediates
• 6.3. Global Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Analgesics
• Antidiabetic Drugs
• Anti-Infective Drugs
• Cardiovascular Drugs
• Anticancer Drugs
• Other Applications
• 6.4. Global Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmaceutical Companies
• Research Institutes
• Contract Manufacturing Organizations
• Other End-Users
• 6.5. Global Active Pharmaceutical Ingredient (API) Intermediate Market, Sub-Segmentation Of Bulk Drug Intermediates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Synthetic Intermediates
• Biotech Intermediates
• Peptide Intermediates
• Steroidal Intermediates
• Amino Acid Intermediates
• 6.6. Global Active Pharmaceutical Ingredient (API) Intermediate Market, Sub-Segmentation Of Chemical Intermediates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chiral Intermediates
• Heterocyclic Intermediates
• Organometallic Intermediates
• Aromatic Intermediates
• Aliphatic Intermediates

7. Active Pharmaceutical Ingredient (API) Intermediate Market Regional And Country Analysis

• 7.1. Global Active Pharmaceutical Ingredient (API) Intermediate Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Active Pharmaceutical Ingredient (API) Intermediate Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Active Pharmaceutical Ingredient (API) Intermediate Market

• 8.1. Asia-Pacific Active Pharmaceutical Ingredient (API) Intermediate Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Active Pharmaceutical Ingredient (API) Intermediate Market

• 9.1. China Active Pharmaceutical Ingredient (API) Intermediate Market Overview
• 9.2. China Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Active Pharmaceutical Ingredient (API) Intermediate Market

• 10.1. India Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Active Pharmaceutical Ingredient (API) Intermediate Market

• 11.1. Japan Active Pharmaceutical Ingredient (API) Intermediate Market Overview
• 11.2. Japan Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Active Pharmaceutical Ingredient (API) Intermediate Market

• 12.1. Australia Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Active Pharmaceutical Ingredient (API) Intermediate Market

• 13.1. Indonesia Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Active Pharmaceutical Ingredient (API) Intermediate Market

• 14.1. South Korea Active Pharmaceutical Ingredient (API) Intermediate Market Overview
• 14.2. South Korea Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Active Pharmaceutical Ingredient (API) Intermediate Market

• 15.1. Western Europe Active Pharmaceutical Ingredient (API) Intermediate Market Overview
• 15.2. Western Europe Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Active Pharmaceutical Ingredient (API) Intermediate Market

• 16.1. UK Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Active Pharmaceutical Ingredient (API) Intermediate Market

• 17.1. Germany Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Active Pharmaceutical Ingredient (API) Intermediate Market

• 18.1. France Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Active Pharmaceutical Ingredient (API) Intermediate Market

• 19.1. Italy Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Active Pharmaceutical Ingredient (API) Intermediate Market

• 20.1. Spain Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Active Pharmaceutical Ingredient (API) Intermediate Market

• 21.1. Eastern Europe Active Pharmaceutical Ingredient (API) Intermediate Market Overview
• 21.2. Eastern Europe Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Active Pharmaceutical Ingredient (API) Intermediate Market

• 22.1. Russia Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Active Pharmaceutical Ingredient (API) Intermediate Market

• 23.1. North America Active Pharmaceutical Ingredient (API) Intermediate Market Overview
• 23.2. North America Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Active Pharmaceutical Ingredient (API) Intermediate Market

• 24.1. USA Active Pharmaceutical Ingredient (API) Intermediate Market Overview
• 24.2. USA Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Active Pharmaceutical Ingredient (API) Intermediate Market

• 25.1. Canada Active Pharmaceutical Ingredient (API) Intermediate Market Overview
• 25.2. Canada Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Active Pharmaceutical Ingredient (API) Intermediate Market

• 26.1. South America Active Pharmaceutical Ingredient (API) Intermediate Market Overview
• 26.2. South America Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Active Pharmaceutical Ingredient (API) Intermediate Market

• 27.1. Brazil Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Active Pharmaceutical Ingredient (API) Intermediate Market

• 28.1. Middle East Active Pharmaceutical Ingredient (API) Intermediate Market Overview
• 28.2. Middle East Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Active Pharmaceutical Ingredient (API) Intermediate Market

• 29.1. Africa Active Pharmaceutical Ingredient (API) Intermediate Market Overview
• 29.2. Africa Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Active Pharmaceutical Ingredient (API) Intermediate Market Competitive Landscape And Company Profiles

• 30.1. Active Pharmaceutical Ingredient (API) Intermediate Market Competitive Landscape
• 30.2. Active Pharmaceutical Ingredient (API) Intermediate Market Company Profiles
  • 30.2.1. Hetero Labs Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Aurobindo Pharma Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Ipca Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Cipla Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Active Pharmaceutical Ingredient (API) Intermediate Market Other Major And Innovative Companies

• 31.1. Cadila Pharmaceuticals Ltd.
• 31.2. Lupin Ltd.
• 31.3. Torrent Pharmaceuticals Ltd.
• 31.4. Mankind Pharma Ltd.
• 31.5. Divis Laboratories Ltd.
• 31.6. Laurus Labs Ltd.
• 31.7. Jubilant Pharmova Ltd.
• 31.8. Piramal Pharma Ltd.
• 31.9. Cambrex Corporation
• 31.10. Alembic Pharmaceuticals Ltd.
• 31.11. Granules India Ltd.
• 31.12. JB Chemicals and Pharmaceuticals Ltd.
• 31.13. Hovione Holdings S.A.
• 31.14. Vasudha Pharma Chem Ltd.
• 31.15. Concord Biotech Ltd.

32. Global Active Pharmaceutical Ingredient (API) Intermediate Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Active Pharmaceutical Ingredient (API) Intermediate Market

34. Recent Developments In The Active Pharmaceutical Ingredient (API) Intermediate Market

35. Active Pharmaceutical Ingredient (API) Intermediate Market High Potential Countries, Segments and Strategies

• 35.1 Active Pharmaceutical Ingredient (API) Intermediate Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Active Pharmaceutical Ingredient (API) Intermediate Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Active Pharmaceutical Ingredient (API) Intermediate Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer